918搏天堂

                                       Fighting Cancer Metastasis andHeavy Metal ToxicitiesWithModified Citrus Pectin
Despite billions of research dollars spent every year, cancer remains the second leading killer of Americans. One reason cancer is so lethal is its tendency to metastasize to essential organs throughout the body.Certain malignancies (like brain tumors) kill by infltrating into healthy tissues, but the vast majority of cancer deaths occur when tumor cells enter the blood and lymphatic systems and travel to the liver, lungs, bones, and other distant parts of the body.
Unfortunately, there have been few effective approaches to preventing cancer metastasis. The encouraging news is that a specialized fruit polysaccharide called modifed citrus pectin has demonstrated unique properties in blocking cancer cell aggregation, adhesion, and metastasis.1Clinical research shows that modifed citrus pectin helps limit disease progression in men with advanced prostate cancer.2 In addition to its cancer-inhibiting effects, modifed citrus pectin shows promise in chelating toxic heavy metals that can be so damaging to overall health.3Here, we’ll explore how this novel compound offers such distinctive and protective effects. > >

What is Modifed Citrus Pectin?
  The American Cancer Society recommends that adults eat fve servings of fruits and vegetables each day in order to help reduce cancer risk.4 One way to get some of the benefts of citrus fruits such as oranges and grapefruits is with modifed citrus pectin.
  Pectin is a naturally occurring substance found in the cell walls of most plants and especially concentrated in the peel and pulp of citrus fruits (lemons,limes, oranges, and grapefruits), plums, and apples.It was frst identifed in 1825, but home cooks had long used fruits with high levels of pectin in jams and marmalades because of their gelling properties. While pectin provides little nutritional content, this carbohydrate acts as a benefcial type of soluble dietary fber.
  Researchers attempted to fnd a process to alter pectin to create a food supplement that would allow the body to beneft from its various health-promoting properties.Recently, scientists have been able to use pH and temperature modifcations to break down pectin’s long,branched chains of polysaccharides into shorter, unbranched lengths of soluble fber moleculesthat dissolve easily in water. The result, modifed citrus pectin (MCP), is a substance that is rich in galactose residues, which are easily processed by the digestive system and absorbed into the bloodstream.5 Scientists continue to refne MCP in their quest for a more active and effective agent.
  Preventing Cancer Metastasis Modifed citrus pectin is thought to be useful in the prevention and treatment of metastatic cancer, especially in solid tumors like melanoma and cancers of the prostate, colon, and breast. Scientists believe that MCP works by inhibiting two key processes involved in cancer progression: angiogenesis and metastasis.6,7 Angiogenesis is the process in which cancer cells establish their own blood supply to fuel their growth.Metastasis occurs when cancer cells break away from the original tumor, enter the bloodstream or lymphatic system, and form a new tumor in a different organ or other parts of the body.8 Secondary or metastatic cancers often pose more life-threatening circumstances than the original tumor.
  As scientists begin to decipher the process of how cells receive, interpret, and relay the signals that recruit them to form new tumors,9 they are focusing their attention on molecules called galactose-binding lectins, or galectins. Galectins are overexpressed adhesion and blood vessel-attracting surface moleculesthat are thought to be involved in the spread of cancer.6 A growing number of small studies in humans and animals have reported that MCP interferes withthe cancer cell’s interactions with other cancer cells by acting as a galectin-3 antagonist—that is, an agent that blocks the normal activity of galectins.
  Via the mechanism of galectin-3 antagonism, MCP appears to disrupt the processes that allow cancer cells to communicate with one another. When the MCP molecules bind to receptors on the surface of cancer cells, they block galectin-3 and other molecules from penetrating into nearby healthy tissue to create a new tumor and establish the tumor’s blood supply(angiogenesis). In this way, MCP seems to play a role in preventing cancerous tumors from metastasizing and spreading to other organs—one of the main causes of death from cancer.
  When MCP interferes with cancer cells trying to form a new tumor, the cancer cells circulate in the bloodstream until they die. By working to inhibit thespread of cancer, MCP keeps the body’s immune system from becoming overwhelmed by an increasingcancer cell load.10Modifed Citrus Pectin’s Effects in Prostate Cancer
Prostate cancer is the most common cancer diagnosed in men in the United States. One in six American men will be diagnosed with prostate cancer during his lifetime. The American Cancer Society (ACS) estimates that 28,660 men die of prostate cancer annually,with only lung cancer more lethal to men.11 The ACS estimates a fve-year survival rate of nearly 100% formen whose prostate cancer is diagnosed and treated at an early stage. But for those men with late stage,metastatic prostate cancer, the treatment options are very limited.
  One of the frst promising studies to show the potential of MCP to inhibit prostate cancer metastasis was published in the Journal of the National Cancer Institute in 1995. Laboratory rats were injected with human prostate cancer cells and divided into four groups. The control group received plain water and the other groups received water with varying concentrations of MCP. After 30 days, only 50% of the rats that drank water with MCP (0.1% weight/volume) had any metastases, while 94% of the rats that drank regular water had cancer metastasize to their lungs. The researchers called for further study to determine both“the role of galectin-3 in normal and cancerous prostate tissues” and “the ability of modifed citrus pectin to inhibit human prostate metastasis in nude mice.”12
  In 1999, Dr. Stephen Strum, an oncologist specializing in prostate cancer and a respected member of Life Extension’s Scientifc Advisory Board, and his colleagues were the frst to show the positive effects of MCP on humans with advanced prostate cancer.In a paper presented at an International Conference on Diet and Prevention of Cancer, they reported that fve of seven men with advanced prostate cancer and unable to beneft from conventional treatment had a positive response after taking MCP every day for three months or longer. The response was measured by an increase in prostate-specifc antigen doubling time (PSADT), which measures the rate at which blood levels of prostate-specifc antigen (PSA) rise. Since PSA is a marker of prostate cancer progression or recurrence,longer PSA doubling time is associated with slower disease progression and is thus desirable. One of the fve patients had no increase to his PSA level at all.13
  A more recent study led by Brad Guess and Drs.Mark Scholz and Stephen Strum also found that MCP increases the PSA doubling time. In this phase II pilot study of 10 men whose prostate cancer had returned after an initial treatment with surgery or radiation, PSADT increased in eight (80%) of the 10 men aftertaking MCP for 12 months.14
  Dr. Strum told Life Extension, “My clinical experience using MCP in prostate cancer has been that it slows PSA doubling time in the majority of patients taking the standard dose of 5 grams three times per day. Because this treatment is well tolerated, I use MCP in situations where sustained increases in PSA may occur.” In a study published in 2007, 49 patients with advanced prostate cancer and few treatment options were given oral doses of MCP powder diluted in water and juice three times a day at eight-hourintervals for a four-week cycle. After two cycles of treatment with MCP, 21% of the patients had a clinical beneft of disease stabilization or improved quality of life; 12% had stable disease for more than 24 weeks. One patient with stage IV metastatic prostate cancer showed a 50% decrease in serum PSA level after 16 weeks of treatment, improving his quality of life and also decreasing pain. “MCP seems to have positive impacts especially regarding clinical beneft and life quality for patients with far advanced solid tumors,” the researchers concluded.2
  Modifed Citrus Pectin and Chelation Beyond its benefts in fghting cancer metastasis,MCP may have applications in mitigating the health dangers posed by toxic heavy metals. Chelation therapy is a chemical process in which a substance is used to bind molecules, such as heavy metals or minerals,and hold them tightly so that they can be removed from a system, such as the body. Chelation can help rid the body of excess or toxic metals, but it is not known if this reduces artery disease risk. Chelation is used to treat lead and mercury poisoning.15,16
  In most instances, chelation therapy involves the infusion of compounds via a catheter placed in an arm vein. This procedure must be done in a clinical setting over a specifed course of treatments. In contrast,chelation therapy using MCP is done via the oral route
and can be administered to the patient in almost any clinical setting, since the supplement can be ingested anywhere.
  A pilot trial evaluating MCP’s chelating effects provided evidence that orally administered MCP signifcantly increases urinary excretion of toxic metals.In a study published in 2006, eight healthy individuals were given 15 grams of MCP daily for fve days and 20 grams of MCP on day six. Twenty-four hour urine samples were collected on days one and six and analyzed for toxic and essential elements. The investigators reported that signifcant urinary excretion of arsenic, mercury, cadmium, and lead increased within one to six days of MCP treatment. There was a 150% increase in the excretion of cadmium and a 560% increase in lead excretion on day six.3 Essential minerals such as calcium, zinc, and magnesium were not seen to increase in the urine analysis, indicating that MCP treatment did not deplete these nutrients.
  In a case study report, fve patients with different illnesses were given MCP (PectaSol®) alone or as an MCP/alginate combination (PectaSol® Chelation Complex™) for up to seven months. Each one had a gradual decrease of total heavy metal burden, which is believed to have played an important role in the patients’ recovery and health maintenance. Thepatients had a 74% average decrease in toxic heavy metals after treatment. The authors report this is the“frst known documentation of evidence” of a possible correlation of positive clinical outcomes and a reduction of toxic heavy metal load using MCP alone or as an MCP/alginate complex. They recommend “further studies be performed to confrm the effectiveness of this gentle non-toxic chelating system as an alternative to harsher chelators in the treatment of patients with a heavy metal body burden.”17
  Lead toxicity is an ongoing concern worldwide,and the long-lasting effects of lead exposure in children are especially troubling. A 2008 pilot study at the Children’s Hospital of Zhejiang University, Hangzhou,China looked at whether MCP® could mitigate lead toxicity in children with high blood levels of lead. Seven children hospitalized with toxic lead levels, aged fve to 12, were given 15 grams of MCP (PectaSol®) per day in three divided dosages. Blood serum and 24-hour urine excretion analysis were performed on days 0,14, 21, and 28. Two patients were released after two weeks, three patients were released after three weeks,and two patients were released after four weeks when their blood lead levels had dropped below the criterion. All of the children had a signifcant increase in urinary excretion of lead. The authors recommend further studies to confrm the effectiveness and safetyof MCP as a lead chelator.18
  Scientists believe that the ability of MCP (PectaSol®)to chelate toxic metals arises from a low molecular weight pectin that contains 10% rhamnogalacturonan II molecular side groups, which are known to selectively bind heavy metals with a strong affnity.Subsequently, these metal–pectin complexes are eliminated in the urine.3

Understanding Galectin-3
  Modifed citrus pectin’s cancer-fghting potential may arise from its ability to interact with specialized proteins called galectins.1
  Galactose-binding lectins, or galectins, are carbohydrate-binding proteins detected within some cancer cells that help the cells clump or cluster together more easily. This may facilitate the growth and spread of certain types of cancer. Among the galectins, scientists believe that galectin-3 may be particularly important in numerous processes involved in cancer,such as cancer adhesion, migration, progression, and metastasis.23
  A growing number of studies suggest that increased levels of galectin-3 in the blood or tissue are associated with more frequent cancer metastasis or an increased stage of tumor progression.24 There is still some controversy in this area, as other data indicate that low or absent galectin-3 levels correlate with more aggressive tumors.25,26 Other fndings suggest that intracellular galectin-3 exerts an anti-apoptotic effect, protecting cancer cells against programmed cell death by affecting mitochondrial function.23,27
  At this time, scientists believe that MCP may help fght certain cancers by binding with galectin-3 to help decrease cancer cell aggregation, adhesion, and metastasis.1
  Further research is needed to determine if MCP can likewise block galectin-3’s anti-apoptotic effects.Such a fnding would represent a breakthrough in cancer therapy, pointing to a potentially synergistic role of MCP in combination with other cancer therapies that
target mitochondrial function.

Using Modifed Citrus Pectin
Research indicates that MCP may hold health applications in signifcantly increasing the urinary excretion of metals3,17,18 and in inhibiting tumor growth and metastasis.19-21
  Side effects from citrus pectin are rare and occur primarily in patients with citrus fruit allergies.10
  According to the Natural Standards Monograph on MCP, “some experts caution that neither citrus pectin nor all ‘modifed’ citrus pectins have the same effects as MCP. Citrus pectin does not have the short polysaccharide chains as MCP, and ‘modifed’ pectin could indicate that the pectin has been altered in some way,but not necessarily have the shorter polysaccharide chains.”22
  MCP provides superior benefts to unmodifed citrus pectin because its shorter, galactose-rich polysaccharide chains allow for better absorption and utilization by the body. Further, its galactose-rich side chains allow MCP to bind galactose-binding lectins on the surface of certain cancer cells to help impede cancer adhesion and metastasis.1
  Make sure that the MCP you are using is one that has been researched and studied in the various clinical trials discussed in this article.
  Nutritional scientists recommend taking MCP on an empty stomach. Dosages range from 6 to 30 grams daily in divided doses. A typical daily dosage is 5 grams,three times daily.

Conclusion
  Modifed citrus pectin is an intriguing substance that continues to be studied in an effort to determine its full therapeutic potential. It appears to be a promising agent that can keep some advanced cancers in check by limiting the growth of new tumors, and by affecting the primary cancer as well. MCP also appears to show some promise as a natural, non-toxic chelating agent that binds to heavy metals like cadmium, lead, mercury, and arsenic and helps the body excrete them in the urine.
  Not all citrus pectin products are alike. Be sure to utilize modifed citrus pectin (MCP) containing short polysaccharide chains such as the preparations utilized in the clinical studies discussed in this article.Scientists continue to refne MCP preparations, which may also result in greater effcacy.

If you have any questions on the scientifc content of this article, please call a Life Extension
Health Advisor at 1-800-226-2370.

References
1. No authors listed. Modifed citrus pectin-monograph. Altern Med Rev. 2000 Dec;5(6):573-5.
2. Azemar M, Hildenbrand B, Haering B, Heim ME, Unger C.Clinical beneft in patients with advanced solid tumors treated with modifed citrus pectin: a prospective pilot study. Clin Med Oncol. 2007;1:73–80.
3. Eliaz I, Hotchkiss AT, Fishman ML, Rode D. The effect of modifed citrus pectin on urinary excretion of toxic elements. Phytother Res.2006 Oct;20(10):859-64.
4. Kushi LH, Byers T, Doyle C, et al. American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2006 Sep;56(5):254-81.
5. Available at: http://www.mdanderson.org/departments/cimer/display.cfm?id=35F6603EF06A 11D4-810200508B603A14&meth
od=displayFull&pn=6EB86A59-EBD9-11D4-810100508B603A14.Accessed June 17, 2008.
6. Glinskii OV, Huxley VH, Glinsky GV, et al. Mechanical entrapment is insuffcient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia. 2005 May;7(5):522-7.
7. Johnson KD, Glinskii OV, Mossine VV, et al. Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. Neoplasia. 2007 Aug;9(8):662-70.
8. Available at: http://www.cancer.gov. Accessed June 17, 2008.
9. Gupta GP, Massague J. Cancer metastasis: building a framework.Cell. 2006 Nov 17;127(4):679-95.
10. Available at: http://cancer.ucsd.edu/outreach/publiceducation/cams/modifedcitrus.asp. Accessed June 17, 2008.
11. American Cancer Society, Inc. Cancer Facts & Figures 2008.
12. Pienta KJ, Naik H, Akhtar A, et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modifed citrus pectin. J Natl Cancer Inst. 1995 Mar 1;87(5):348-53.
13. Strum S, Scholz M, McDermed J, McCulloch M, Eliaz I. Modifed citrus pectin slows PSA doubling time: a pilot clinical trial. Paper presented at: International Conference on Diet and Prevention of Cancer; May 1999; Tampere, Finland.
14. Guess BW, Scholz MC, Strum SB, et al. Modifed citrus pectin (MCP) increases the prostate-specifc antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Prostatic Dis. 2003;6(4):301-4.
15. Kosnett MJ, Wedeen RP, Rothenberg SJ, et al. Recommendations for medical management of adult lead exposure. Environ Health Perspect. 2007 Mar;115(3):463-71.
16. Brodkin E, Copes R, Mattman A, Kennedy J, Kling R, Yassi A.Lead and mercury exposures: interpretation and action. CMAJ.2007 Jan 2;176(1):59-63.
17. Eliaz I, Weil E, Wilk B. Integrative medicine and the role of modifed citrus pectin/alginates in heavy metal chelation and detoxifcation--fve case reports. Forsch Komplementmed. 2007 Dec;14(6):358-64.
18. Zhao ZY, Liang L, Fan X, et al. The role of modifed citrus pectin as an effective chelator of lead in children hospitalized with toxic lead levels. Altern Ther Health Med. 2008 Jul;14(4):34-8.

19. Nangia-Makker P, Hogan V, Honjo Y, et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modifed citrus pectin. J Natl Cancer Inst. 2002 Dec18;94(24):1854-62.
20. Hayashi A, Gillen AC, Lott JR. Effects of daily oral administration of quercetin chalcone and modifed citrus pectin on implanted colon-25 tumor growth in Balb-c mice. Altern Med Rev. 2000 Dec;5(6):546-52.
21. Hsieh TC, Wu JM. Changes in cell growth, cyclin/kinase,endogenous phosphoproteins and nm23 gene expression in human prostatic JCA-1 cells treated with modifed citrus pectin. Biochem Mol Biol Int. 1995 Nov;37(5):833-41.
22. Available at: http://www.naturalstandard.com/index-abstract.aspcreate abstract=/monographs/herbssupplements/modifedcitruspectin.asp. Accessed December 8, 2008.
23. Nangia-Makker P, Nakahara S, Hogan V, Raz A. Galectin-3 in apoptosis, a novel therapeutic target. J Bioenerg Biomembr. 2007 Feb;39(1):79-84.
24. Takenaka Y, Fukumori T, Raz A. Galectin-3 and metastasis.Glycoconj J. 2004;19(7-9):543-9.
25. Merseburger AS, Kramer MW, Hennenlotter J, et al. Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival. World J Urol. 2008 Dec;26(6):637-42.
26. Turkoz HK, Oksuz H, Yurdakul Z, Ozcan D. Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. Endocr Pathol. 2008 Summer;19(2):92-6.
27. Nakahara S, Oka N, Raz A. On the role of galectin-3 in cancer
apoptosis. Apoptosis. 2005 Mar;10(2):267-75.